Oncology Data Advisor

A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care by i3 Health

Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape. Click here to claim your credit for this podcast:

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.

Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Click here to go back and listen to module 1 of this podcast series: https://bit.ly/4iYmYD2 Click here to claim your CME/NCPD credit: https://bit.ly/44yO9RB

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Click here to listen to module 2 of this podcast series: bit.ly/44yO9RB Click here to claim your CME/NCPD credit: bit.ly/4iYmYD2

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical. In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease. Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice. Click below to access these valuable resources: Accredited CME/NCPD Podcast: bit.ly/3B4gSB1 Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0 Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn

As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education. Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update

In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care. Learn more at: https://oncdata.com/digital-pathology-osama-khan

The role of artificial intelligence (AI) and machine learning (ML) in precision oncology has expanded rapidly, offering promising tools for clinicians and researchers to deliver more targeted and efficient care. During the 2024 San Antonio Breast Cancer Symposium (SABCS), Fellows Forum member Dr. Jasmin Hundal conducted an interview with Ian Maurer, Chief Technology Officer at GenomOncology, to explore the applications, challenges, and future directions of AI in oncology. Learn more at: https://oncfellows.com/how-ai-is-revolutionizing-precision-oncology

Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney

In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes. Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/

The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice. Learn more at: https://oncdata.com/zanidatamab-biliary-tract-cancer-james-harding/

As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.

The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health

i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care! Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.

Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC. Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care

Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, discusses additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast. Click this link to claim your free CPE certificate: https://i3health.com/course-information/chronic-kidney-disease

Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-view At last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Immune-Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes (IRAEs): The Nurse’s View, chaired by Blanca Ledezma, MSN, NP, AOCNP®, Hematology/Oncology Nurse Practitioner at UCLA Health. With numerous advances in the immunotherapy space occurring since the symposium was held, Oncology Data Advisor Editorial Board member Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, sat down to discuss some of these updates in lung cancer and her own insights on optimal management of IRAEs from the nursing perspective.

In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including: • Her own background in the technology industry and why she joined iCAD • The products and solutions that iCAD offers • How iCAD utilizes AI to improve mammography accuracy • The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes • Their recent partnership with Densitas and CancerIQ and their impact on breast health • What distinguishes iCAD’s AI algorithms from other solutions in the market • The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success • Recommendations for clinicians in practice to learn about and integrate AI into their workflow • And more!

In this Fellows Forum podcast episode, Dr. Richa Thakur, Palliative Care Physician and Hematology/Oncology Fellow at Northwell Health, speaks with Dr. Janet Abrahm, one of the founders of the field of palliative care in the United States. Dr. Abrahm shares insights into her career and research in palliative care, including: • How palliative care in oncology isn’t just for end of life—it’s for enhancing patient outcomes • How palliative care serves as a partner for the oncology team • The value of palliative care training for hematology/oncology fellows • How to cope with the moral distress and compassion fatigue that clinicians may experience when treatment doesn’t work for their patients • The stages of grief (denial, anger, bargaining, depression, acceptance) and how they can be experienced by both patients and clinicians • The importance for both oncology and palliative care fellows to find an outlet for their grief • Dr. Abrahm’s website and book, “Comprehensive Guide to Supportive and Palliative Care for Patients with Cancer,” which feature a wealth of information for busy practicing oncology and palliative care clinicians • And more!

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.

Investigating Axicabtagene Ciloleucel for R/R Central Nervous System Lymphoma: Lakshmi Nayak, MD by i3 Health

Combating Health Disparities Through More Equitable Screening: Chyke Doubeni, MD, MPH by i3 Health

Multicancer Early Detection - What's Your Opinion? with Chyke Doubeni, MD, MPH by i3 Health

The Latest Data on Zanidatamab for HER2-Positive Biliary Tract Cancer: Shubham Pant, MD by i3 Health

Biomarker Documentation in the Community Setting and Clinical Decision Support: Daniel Rubin, PharmD by i3 Health

Community Oncology Pharmacists - Their Crucial Role and Clinical Impact: Andrea Roman, PharmD, BCOP by i3 Health

Cancer and Careers - Empowering People with Cancer to Thrive in the Workplace: Rebecca Nellis, MPP by i3 Health

Exploring Association of FGFR3 Alterations in Urothelial Cancer: Arlene Siefker-Radtke, MD by i3 Health

Representing Symptom Research and Nursing at ASCO: Natalie Jackson-Carroll, PhD, APRN, FNP-C by i3 Health

Worth the Wait - Supporting Young Adult Cancer Survivors on the Path to Parenthood: Mike Scherer by i3 Health

Optimizing Sacituzumab Govitecan Tolerability in TNBC With Early Management: Antonio Llombart, MD by i3 Health

Understanding Lung Cancer Diagnostic Trends to Inform Therapeutic Development: Jess Paulus, SCd by i3 Health

Intuitively Designing Clinical Trials to Empower Patients: Ishwaria Subbiah, MD by i3 Health

Updated Results from the SPOTLIGHT and EV-302 Trials at ASCO: Ahsan Arozullah, MD, MPH by i3 Health

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Erica Fortune, PhD, Vice President of Research at Cancer Support Community, to discuss her team’s poster entitled, “Head and Neck Cancer (HNC) Survivors: Long-Term Nutrition Impact Symptoms, Eating Problems, and Barriers to Care Impact Psychosocial Health.” In this podcast, Dr. Fortune delves further into this topic, including: Background about long-term side effects and quality-of-life impacts experienced by HNC survivors Cancer Support Community’s survey designed to further investigate these challenges The results that the study found regarding nutrition, eating problems, and barriers to care that survivors experience How Cancer Support Community plans on using the survey results to improve survivorship and address psychosocial impacts experienced by long-term HNC survivors A preview of other topics that Cancer Support Community is excited to cover as a member organization of the Oncology Data Advisor Editorial Board And more!

At the conclusion of this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, Monzr Al Malki, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, sat down with Richa Thakur, a Palliative Care Physician and Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health, to discuss his oral abstract presentation entitled “Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.”

This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. Check out the episode to hear more about: • Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI • Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps • Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care • The efficacy of these solutions and how they can be used in the clinic • The lung cancer portfolio that Qure.ai showcased at ASCO • Other innovations coming down the pipeline • And more!

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!